3 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
7 Jun 23
Regulation FD Disclosure
7:31am
addressed concerns about DILI risk: ▪ Signal appears modest in intensity ▪ Potentially manageable with appropriate monitoring, which Akebia notes
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
30 May 23
Regulation FD Disclosure
7:34am
appears modest in intensity and is potentially manageable with appropriate monitoring. The OND also acknowledged Akebia’s comments that such monitoring
8-K
AKBA
Akebia Therapeutics Inc.
30 May 23
Regulation FD Disclosure
7:34am
available than in the clinical trial. The OND concluded that while DILI remains a concern, the DILI signal appears modest in intensity
- Prev
- 1
- Next